Evidence map›Paper›PMID 40860496›Full record

ArticleJournal of pain research2025

Efficacy and Safety of the Bushen Quhan Zhiwang Decoction to Achieve Clinical Deep Remission in Rheumatoid Arthritis: Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial.

Longxiao Liu, Jinping Wang, Yanyu Chen, Yunlong Fang, Zihan Wang, Xiaojing Liu, Lidong Hong, Qingwen Tao, Yuan Xu

Abstract read
In one paragraph

Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Longxiao Liu *National Center for Integrative Medicine; Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People's Republic of China.ORCID 0009-0003-3239-1851
Jinping Wang *National Center for Integrative Medicine; Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Yanyu ChenNational Center for Integrative Medicine; Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Yunlong FangNational Center for Integrative Medicine; Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Zihan WangNational Center for Integrative Medicine; Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People's Republic of China.ORCID 0000-0003-4588-480X
Xiaojing LiuNational Center for Integrative Medicine; Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Lidong HongNational Center for Integrative Medicine; Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Qingwen TaoNational Center for Integrative Medicine; Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Yuan XuNational Center for Integrative Medicine; Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by significant disability, with effective management of disease activity and pain constituting critical clinical objectives. The herbal formulation Bushen Quhan Zhiwang Decoction (BQZD) has demonstrated potential efficacy in symptom alleviation, suggesting a promising role in achieving sustained clinical remission in RA. The present study aims to systematically evaluate the efficacy and safety profile of BQZD for managing RA disease activity and pain relief. Patients and Methods: This randomized, double-blind, placebo-controlled, single-center clinical trial will enroll a total of 72 RA patients, randomly assigning them into either the intervention group (n=36) receiving BQZD or the placebo control group (n=36). Participants will consume either BQZD or placebo (100 mL, twice daily) over a 12-week intervention period. Clinical assessments are scheduled at enrollment and subsequently at 4-week intervals, continuing through the 16-week mark post-intervention initiation. The primary outcome measure is the Disease Activity Score for 28 joints (DAS28). Secondary outcome variables include visual analogue scale (VAS) pain scores, mechanical pain threshold (MPT), central sensitization inventory (CSI), patient-reported outcomes (PROs), Traditional Chinese medicine (TCM) symptom scores, and biomarkers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Safety endpoints will encompass monitoring of hematological parameters, urinalysis results, and adverse events. Discussion: This study seeks to generate robust clinical evidence verifying the therapeutic efficacy and safety of BQZD for alleviating pain and achieving deep remission in RA patients. These findings are anticipated to facilitate broader integration of traditional herbal medicine within clinical practice. Additionally, this research endeavors to provide clinically relevant insights into precision treatments for RA by integrating traditional Chinese medicine and Western medical approaches, and aims to lay foundational evidence for future investigations into underlying regulatory mechanisms and potential therapeutic targets of TCM.

Indexed as

Bushen Quhan Zhiwang Decoctionclinical deep remissionpainrandomized controlled trialrheumatoid arthritis

Identifiers

PMID40860496
PMCPMC12377374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.